Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 1, 2018. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights data.
| Metric | Value as of Jan 31, 2018 |
|---|---|
| Total Issued Ordinary Shares | 5,372,800,870 |
| Share Par Value | 25 pence each |
| Treasury Shares | 414,605,950 |
| Total Voting Rights | 4,958,194,920 |
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. No comparative data for previous reporting periods is included in this specific notification.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a statutory notification of share capital and does not contain operational commentary or forward-looking statements.
Investor Verification Checklist
- Verify the total number of voting rights (4,958,194,920) to determine notification thresholds under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
- Confirm the number of shares held in Treasury (414,605,950) when calculating outstanding share counts.
- Review the Company's Form 20-F for comprehensive financial performance data, as this Form 6-K contains only capital structure information.